Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.60 |
| ▸ | BCHE | P06276 | 2/20 | 0.59 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.57 |
| ▸ | CCR3 | P51677 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4505679 | 0.84 | ACHE (0.63) | ACHEBCHECXCR4CCR3 | |
| SCHEMBL6747206 | 0.83 | CXCR4 (0.65) | ACHEBCHECXCR4CCR3 | |
| SCHEMBL12401142 | 0.82 | CXCR4 (0.53) | ACHECXCR4 | |
| Hydrochloric Acid SCHEMBL9537230 | 0.82 | BCHE (0.63) | ACHEBCHECXCR4CCR3 | |
| SCHEMBL4854037 | 0.81 | GAA (0.64) | ACHEBCHECXCR4CCR3 | |
| Hydrochloric Acid SCHEMBL8825453 | 0.81 | BCHE (0.62) | ACHEBCHECXCR4CCR3 | |
| SCHEMBL15338755 | 0.81 | CXCR4 (0.61) | ACHEBCHECXCR4CCR3 | |
| SCHEMBL2980930 | 0.80 | DRD2 (0.67) | ACHEBCHECXCR4CCR3 | |
| SCHEMBL7501904 | 0.79 | DRD2 (0.63) | ACHEBCHECXCR4CCR3 | |
| Hydrochloric Acid SCHEMBL9538343 | 0.79 | GAA (0.63) | ACHEBCHECXCR4CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575208-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-05 | — | — | US | disclosed |
| US-8440706-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-14 | — | — | US | disclosed |
| US-8372873-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-7985762-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-07 | — | — | US | disclosed |
| US-7964624-B1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-21 | — | — | US | disclosed |
| US-20100272681-A1 | Inhibitors of Serine Proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-28 | — | — | US | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, PRSS3, PRSS2 | ACHE 2639/4885BCHE 1362/4885CXCR4 3814/4885 |
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | ACHE 2639/4885BCHE 1362/4885CXCR4 3814/4885 |
| US-20100272681-A1 | Inhibitors of Serine Proteases | SERPINB1, PRSS1, SPINT2 | ACHE 2815/4885BCHE 1477/4885CXCR4 2147/4885 |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | ACHE 3189/4885BCHE 1703/4885CXCR4 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.